Company News: Page (1) of 1 - 06/06/12

Medmeme, LLC. Views Respiratory Disease Biological Reality and Treatment Potential

(June 06, 2012)

New York, NY (PRWEB) June 06, 2012

Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms, announces release of the new syndicated TrendsmemeTM Report: Respiratory Diseases. In terms of global spending on drugs, it is estimated that the respiratory disease category ranked third, after oncology and anti-diabetes, at $36.3 billion sales in 2010; with projected annual growth of 2% to 3%. While this TrendsmemeTM Report discusses chronic respiratory disease in general, it has a particular and detailed focus on three specific diseases: asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension (PAH). Because chronic respiratory diseases can take as much as decades to develop in patients, and are currently both under diagnosed and undertreated, there exists a broad window of opportunity for research to develop new treatments and to monetize scientific and medical advances. However, because of the inherently complex and multifaceted nature of the diseases, it is unlikely that new, single blockbuster drugs will emerge to dominate the market for intervention. Rather, multi-therapy approaches will be dominate, and success will come from realignment of the R&D/business model to biological reality, a province highly attractive to smaller, more focused respiratory disease companies, as reflected in the trends outlined in the report.

An indicator in the Medmeme database that identifies treatment leadership and drug sales success is the exposure a drug has had in medical meeting presentations and peer-reviewed journal publishing. Based on this evidence, in 2011 the leading firms offering treatments for asthma were: GlaxoSmithKline, Novartis, Roche, Merck, and AstraZeneca; for COPD they were Novartis, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Nycomed; and for PAH they were Actelion, United Therapeutics, Gilead, Pfizer, and Roche. The leaders in asthma and COPD treatment are entirely large companies, but leading companies in PAH include several smaller companies. The recent announcement by Pfizer signaling it will not continue R&D in the respiratory category indicates potential trends opening opportunities for smaller firms. Other firms active in the category mentioned in the report include both small and large firms. They are: UCB, Teva, Shire, Sepracor, Sanofi, Lilly, J&J/Centocor, Graceway, Forest Lab, Dey, Chiesi, Cephalon, Biogen, Bayer, Amgen, and Abbott. Numerous report charts and graphs reflect evidence of what the future treatment pipeline may look like in terms of companies and drugs.

Medmeme CEO Mahesh Naithani discusses correlation and integration of Medmeme information sources: TrendsmemeTM reports begin with medical meeting presentations abstract and peer reviewed publications abstract information gathered 24/7 from about 14,000 medical conferences and 6000 peer reviewed publications. Adding roughly 1.8 million new abstracts each year to our database. To this current information we add the three-year perspective already in the database. Next, we drill down a sharp focus on the therapeutic category, companies, drugs, people, trials we want to talk about. This gives us the target of information we want to gather and integrate from all our other data platforms to reveal additional trends in disease understanding, R&D activities, treatment patterns, company strategies, unmet needs, opportunities, and challenges. To get the final definition of what should be in the report from all this correlated, targeted, integrated information we use a fine filter to determine the immediate and longer range status of the therapeutic class; the what, who, where, and how of what is going on verified by this cross-matching with the same targeted information on experts, their medical contributions and institutional affiliations, drug and treatment data, clinical trials, and so forth. This TrendsmemeTM Report on respiratory disease is a perfect example of an in-depth attribution of real-life facts that let us understand the dramatic shifts that are taking place in this particular treatment area.

The syndicated TrendsmemeTM Report: Respiratory Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports.

Medmeme, LLC
Yan Barshay, Executive Vice President
+1 212-725-5992
yan(at)medmeme(dot)com

Medmeme, LLC.
Ray Wright, Vice President, Sales
+ 1 508-278-4595
rwright(at)medmeme(dot)com

Read the full story at http://www.prweb.com/releases/2012/6/prweb9576953.htm.

Page: 1

Related Keywords:fishing industry, healthcare provider, cinema industry, radio industry, television industry, music industry, process industry, healthcare policy, government aid, government debt, government contract, government health care, government, national government, government departments, non government organizations (NGO), medical procedure/test, medical research, medical staff, medical specialisation, medical service, medical conditions, restraint of trade, international (foreign) trade, trade dispute, trade agreements, trade policy, trade balance,